Simultaneous Detection of Multiple Familial Hypercholesterolemia Mutations Facilitates an Improved Diagnostic Service in South African Patients at High Risk of Cardiovascular Disease
| Autor: | Nico J. P. de Villiers, Gernot Kriegshäuser, Fritz Kury, Charlotte L. Scholtz, Rochelle Thiart, Maritha J. Kotze, Anne Moritz, Christian Oberkanins |
|---|---|
| Rok vydání: | 2003 |
| Předmět: |
Oncology
medicine.medical_specialty Familial hypercholesterolemia Disease Dna testing Polymerase Chain Reaction Hyperlipoproteinemia Type II South Africa Pharmacotherapy Risk Factors Internal medicine medicine Humans Point Mutation business.industry Point mutation General Medicine medicine.disease Human genetics Endocrinology Amino Acid Substitution Receptors LDL Cardiovascular Diseases LDL receptor lipids (amino acids peptides and proteins) business Lipoprotein |
| Zdroj: | Molecular Diagnosis. 7:169-174 |
| ISSN: | 1084-8592 |
| DOI: | 10.1007/bf03260034 |
| Popis: | DNA testing can provide a definitive diagnosis of familial hypercholesterolemia (FH), even in the absence of the clinical characteristics of this inherited cardiovascular disease (CVD) subtype. Our aim was to design a rapid diagnostic assay capable of simultaneously analyzing seven point mutations in the low-density lipoprotein receptor (LDLR) gene, which occur at high frequency in South African FH patients.The test is based on multiplex DNA amplification and hybridization to membrane strips presenting a parallel array of immobilized allele-specific oligonucleotide probes.A reverse-hybridization assay for genotyping LDLR point mutations D154N, D200G, D206E, C356Y, G361V, V408M, and P664L was set-up and validated using pretyped human DNA samples, as well as recombinant plasmid clones containing mutant alleles. The procedure is rapid (6 hours) and may be automated to a large extent.The new FH strip-assay forms an important part of the comprehensive cardiovascular genetic screen offered routinely to high-risk population groups in South Africa. A genetic approach based on FH testing in conjunction with other 'genetic' CVD risk factors is feasible and justified, since the spectrum of disease-related mutations have been defined to a large extent in the genetically distinct population groups of South Africa. Knowledge of a significantly increased CVD risk due to the presence of gene variations, which can be targeted for risk reduction by the avoidance of relevant environmental risk factors and the appropriate treatment, provides a powerful message to motivate people into implementing preventative measures based on their genetic profile. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|